Experienced in Hemoglobin SC Disease

Dr. Leonel Hernandez

Hematology | Oncology
University Of Miami
1475 Nw 12th Ave, 
Miami, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Hemoglobin SC Disease
University Of Miami
1475 Nw 12th Ave, 
Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Leonel Hernandez is a Hematologist and an Oncologist in Miami, Florida. Dr. Hernandez is rated as an Experienced provider by MediFind in the treatment of Hemoglobin SC Disease. His top areas of expertise are Metastatic Uveal Melanoma, Melanoma of the Eye, Melanoma, and Breast Cancer.

His clinical research consists of co-authoring 52 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in FL
Hospital Affiliations
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

UNIVERSITY OF MIAMI
1475 Nw 12th Ave, Miami, FL 33136

Additional Areas of Focus

Dr. Hernandez has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Enrollment Status: Recruiting
Publish Date: July 28, 2025
Intervention Type: Drug, Behavioral, Other
Study Drugs: Goserelin, Anastrozole, Exemestane, Fulvestrant, Tamoxifen
Study Phase: Phase 2
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Enrollment Status: Withdrawn
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drugs: IMCgp100, Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma
Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma
Enrollment Status: Unknown
Publish Date: April 11, 2023
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: IMCgp100
Study Phase: Phase 1/Phase 2
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
Enrollment Status: Terminated
Publish Date: November 01, 2022
Intervention Type: Drug, Biological
Study Drugs: Doxorubicin, Trastuzumab, Cyclophosphamide, Paclitaxel, Epirubicin, Docetaxel, Carboplatin, Fluorouracil
Study Phase: Phase 2
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Procedure, Drug
Study Phase: Phase 2
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Withdrawn
Publish Date: March 10, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
Enrollment Status: Terminated
Publish Date: September 29, 2021
Intervention Type: Procedure, Drug, Genetic, Biological
Study Phase: Phase 2
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
Phase IB Pilot Study of Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
Phase IB Pilot Study of Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: June 21, 2021
Intervention Type: Drug, Device, Procedure, Other
Study Phase: Phase 1
A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
Early Assessment of Response to Dual Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma Using 18F-FLT PET/CT and PET/MR
Early Assessment of Response to Dual Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma Using 18F-FLT PET/CT and PET/MR
Enrollment Status: Terminated
Publish Date: July 17, 2019
Intervention Type: Drug, Device
Study Phase: Phase 1
Phase I Study of MCS110 Combined With Neoadjuvant Dose-Dense Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Phase I Study of MCS110 Combined With Neoadjuvant Dose-Dense Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Enrollment Status: Withdrawn
Publish Date: August 16, 2018
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 1
View 12 Less Clinical Trials

52 Total Publications

Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma.
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma.
Journal: Journal of the American College of Surgeons
Published: October 10, 2025
Similar Doctors
Distinguished in Hemoglobin SC Disease
Dr. Gershwin T. Blyden
Hematology | Oncology
Distinguished in Hemoglobin SC Disease
Dr. Gershwin T. Blyden
Hematology | Oncology
8335 Ne 2nd Ave, 
Miami, FL 
 (4.6 miles away)
305-757-0113
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gershwin Blyden is a Hematologist and an Oncologist in Miami, Florida. Dr. Blyden is rated as a Distinguished provider by MediFind in the treatment of Hemoglobin SC Disease. His top areas of expertise are Sickle Cell Disease, Hemoglobin SC Disease, Hemoglobinopathy, and Hemoglobin C Disease. Dr. Blyden is currently accepting new patients.

Distinguished in Hemoglobin SC Disease
Dr. Thomas J. Harrington
Hematology Oncology | Hematology
Distinguished in Hemoglobin SC Disease
Dr. Thomas J. Harrington
Hematology Oncology | Hematology

University Of Miami

1611 Nw 12 Ave, 
Miami, FL 
 (0.2 miles away)
305-243-4000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Harrington is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Harrington is rated as a Distinguished provider by MediFind in the treatment of Hemoglobin SC Disease. His top areas of expertise are Sickle Cell Disease, Hemoglobin SC Disease, Hemoglobinopathy, Bone Marrow Aspiration, and Cerebral Artery Bypass Surgery. Dr. Harrington is currently accepting new patients.

Distinguished in Hemoglobin SC Disease
Dr. Michel Vulfovich
Hematology Oncology | Hematology | Oncology
Distinguished in Hemoglobin SC Disease
Dr. Michel Vulfovich
Hematology Oncology | Hematology | Oncology

South Broward Hospital District

3501 Johnson St, 
Hollywood, FL 
 (16.0 miles away)
954-265-9976
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michel Vulfovich is a Hematologist Oncology specialist and a Hematologist in Hollywood, Florida. Dr. Vulfovich is rated as a Distinguished provider by MediFind in the treatment of Hemoglobin SC Disease. His top areas of expertise are Sickle Cell Disease, Hemoglobin SC Disease, Familial Colorectal Cancer, and Neuroendocrine Carcinoma of the Cervix. Dr. Vulfovich is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hernandez's expertise for a condition
ConditionClose
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile